冠脉造影术前强化瑞舒伐他汀治疗对循环内皮祖细胞的影响

The Influence of High-Dose Rosuvastatin on Circulating Endothelial Progenitor Cells

目的观察冠脉造影术前24h不同剂量瑞舒伐他汀治疗对循环内皮祖细胞数量的影响,探究冠脉介入术前强化他汀治疗获益的机制。方法将拟行冠脉造影检查的42例患者随机分为2组:10mg组20例,20mg组22例。2组均顿服瑞舒伐他汀治疗。治疗前及治疗24h后(冠脉造影前),流式细胞仪检测患者循环内皮祖细胞数量。根据冠脉造影结果,再将上述2组各分为冠心病组和冠脉造影阴性组2个亚组。结果:治疗后,2组循环内皮祖细胞数量与治疗前相比(10mg组:49.95±24.57vs42.95±21.18;20mg组:57.68±17.62vs48.32±22.47)差异无统计学意义(P>0.05)。2组循环内皮祖细胞数量变化量(7.00±18.94vs9.36±22.44)比较差异无统计学意义(P>0.05)。亚组分析表明,冠心病组服用20mg瑞舒伐他汀24h后循环内皮祖细胞数量较治疗前增加(56.92±12.27vs42.08±21.27),差异有统计学意义(P<0.05)。结论冠心病患者介入术前24h应用20mg瑞舒伐他汀可以提高循环内皮祖细胞数量,可能是冠脉介入术前强化他汀治疗获益的机制之一。

Objective To observe different doses of rosuvastatin on circulating endothelial progenitor cells at 24 hours before coronary angiography （CAC）, and to explore the mechanism of therapeutic benefit of high-dose statin before percutaneous coronary intervention （PCI）. Methods Forty-two cases who were to undergo CAG were randomly divided into two groups： 10 mg group （n=20） and 20 mg group （n=22）. All subjects took rosuvastatin at a draught. Before treatment and 24 hours after treatment （before CAG）, flow cytometry was used to test the number of circulating endothelial progenitor ceils （CEPCs）. According to the results of CAG, the two groups were respectively divided into two subgroups：coronary artery disease （CHD） group and CAG negative group. Results After treatment, the numbers of CEPCs in two groups were not significantly changed （10 mg group：49.95±24.57 vs 42.95±21.18, P 〉 0.05; 20 mg group： 57.68± 17.62 vs 48.32±22.47, P 〉 0.05）. There was no significant difference in the changed number of CEPCs between 10 mg group and 20 mg group （7.00±18.94 vs 9.36±22.44, P 〉 0.05）. The subgroup analysis showed that the number of CEPCs was significantly increased in CHD group than before treatment with 20 mg rosuvastatin（56.92±12.27 vs 42.08±21.27, P 〈 0.05）. Conclusion Taking 20 mg rosuvastatin in patients with CHD at 24 h before PCI increases the number of CEPCs, which may be one of the mechanisms of benefit of high-dose statin therapy before PCI.